[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610304":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":28,"locations":38,"responsibleParty":60,"collaborators":19,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":19,"enrollmentInfo":72,"targetDuration":19,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":41,"whyStopped":19,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"University of Florida","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Platelet function-guided cangrelor titration","EXPERIMENTAL","Patients with PRU levels ≤208 will undergo cangrelor dose reduction to 0.50 mcg\u002Fkg\u002Fmin, while patients with PRU levels \\>208 will undergo dose increase to 1.0 mcg\u002Fkg\u002Fmin. At 2 to 12 hours after dose titration, blood samples will be collected for further PD assessment of platelet reactivity. Patients with PRU values \\>208 will undergo dose increase by 0.25 mc\u002Fkg\u002Fmin up to a maximum of 1.5 mcg\u002Fkg\u002Fmin until a PRU below 208 is achieved, while patients with PRU levels \\\u003C85 will undergo dose reduction to 0.25 mcg\u002Fkg\u002Fmin, being the lowest possible administration rate allowed during the study period. Titration will be performed at 3 time points: baseline (while on 0.75 mcg\u002Fkg\u002Fmin before dose titration); between 2 and 12 hours following dose titration; daily (at the same time for the second dose) for up to a maximum of 3 samples after dose titration.",[13],"Drug: Cangrelor",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","Cangrelor",[9],null,[21,25],{"name":22,"affiliation":23,"role":24},"Dominick J Angiolillo, MD, PhD","University of Florida College of Medicine - Jacksonville","STUDY_CHAIR",{"name":26,"affiliation":23,"role":27},"Luis Ortegra-Paz, MD, PhD","PRINCIPAL_INVESTIGATOR",[29,34],{"name":30,"role":31,"phone":32,"phoneExt":19,"email":33},"Luis Ortega-Paz, MD, PhD","CONTACT","904-244 2060","Luis.Ortega@jax.ufl.edu",{"name":35,"role":31,"phone":36,"phoneExt":19,"email":37},"Andrea Burton, MPH, CCRP","904-244-5617","Andrea.Burton@jax.ufl.edu",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"University of Florida Jacksonville","RECRUITING","Jacksonville","Florida","32209","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-81.65565,30.33218,{"lat":51,"lon":50},[54,57,59],{"name":55,"role":31,"phone":56,"phoneExt":19,"email":33},"Luis Ortega, MD, PhD","904-244-2060",{"name":35,"role":31,"phone":36,"phoneExt":19,"email":58},"andrea.burton@ufhealth.org",{"name":55,"role":27,"phone":19,"phoneExt":19,"email":19},{"type":61,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100610304","phase-4-the-bridging-antiplatelet-therapy-with-cangrelor-2-study-100610304",false,"NCT07225842","The Bridging Antiplatelet Therapy With Cangrelor 2 Study","The Bridging Antiplatelet Therapy With Cangrelor 2 (BRIDGE 2) Study: A Pilot Prospective Cohort, Pharmacodynamic Study of Tailored Cangrelor Bridging Dosing Regimens","BIRDGE 2","Inclusion Criteria:\n\n1. Any patient receiving bridging with standard-dose cangrelor infusion rate of 0.75 mcg\u002FKg\u002Fmin for at least two hours as part of their standard of care.\n2. Age ≥18 years\n3. Provide written informed consent.\n\nExclusion Criteria:\n\n1. Need for urgent surgery\n2. Confirmed or suspected pregnancy (in woman of child-bearing potential) or lactating females\n3. Exposure to any oral P2Y12 inhibitor, oral anticoagulant or glycoprotein IIb\u002FIIIa inhibitor within 48 hours.\n4. Known allergy, and hypersensitivity, or contraindication to cangrelor, mannitol, sorbitol, or microcrystalline cellulose","ALL","18 Years",{"count":73,"type":74},50,"ESTIMATED","INTERVENTIONAL",[77],"PHASE4","The primary aim of this study is to determine rates of patients with optimal platelet reactivity range, defined as PRU levels between 85 and 208, when using a (PFT)-guided titration of cangrelor infusion rate (cangrelor titration) compared to 0.75 mcg\u002Fkg\u002Fmin (standard-dose infusion) for bridging.",[80],"Coronary Arterial Disease (CAD)",[82,83,84],"coronary artery disease","cangrelor","bridge","2026-04-30",{"date":87,"type":88},"2026-05-05","ACTUAL",{"date":90,"type":88},"2026-02-18",{"date":92,"type":74},"2027-11",{"name":5,"class":6},1]